NCT00205725|Completed
Pfizer/IVGTT/Ziprasidone/Olanzapine
Glucose Regulation During Ziprasidone Treatment
Loading search results
Glucose Regulation During Ziprasidone Treatment
Sponsor study identifier
interventional
120
1 country
1
Study Start
November 2000
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2006
Actual (reported)Study Completion
October 2006
Actual (reported)Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions. Antipsychotic treatment may contribute significantly to abnormalities in glucose regulation. Hyperglycemia can contribute to long-term cardiovascular disease risk that may already be increased in patients with schizophrenia due to higher rates of smoking, sedentary life style, obesity and under-treated hypertension and dyslipidemia. This project will characterize the effects on glucose control of the two most commonly prescribed newer antipsychotic medications, ziprasidone and olanzapine, in patients with schizophrenia.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2000
Date type not reportedThis date has not been verified as actual or estimated.
September 13, 2005
Actual (reported)September 20, 2005
Actual (reported)October 2006
Actual (reported)October 2006
Actual (reported)Effects of olanzapine/ziprasidone/haloperidol on glucose regulation
Explore treatment-related effects on glucose effectiveness
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Ziprasidone, Olanzapine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordWashington University School of Medicine, Psychiatry Dept.
St Louis, Missouri, 63110, United States
Haupt DW, Fahnestock PA, Flavin KA, Schweiger JA, Stevens A, Hessler MJ, Maeda J, Yingling M, Newcomer JW. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology. 2007 Dec;32(12):2561-9. doi: 10.1038/sj.npp.1301392. Epub 2007 Mar 21.
Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology. 2005 Jan;30(1):184-91. doi: 10.1038/sj.npp.1300563.
John W. Newcomer, M.D.
Washington University School of Medicine and Florida Atlantic University
120 participants (actual enrollment reported by the registry).
First Submitted
September 13, 2005
First Posted
September 20, 2005
Study Start
November 2000
Date type not reportedThis date has not been verified as actual or estimated.
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
Contact the study team to confirm eligibility.
Primary Completion
October 2006
Actual (reported)Study Completion
October 2006
Actual (reported)Last Updated
March 13, 2014
Record last verified: 2014-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: